{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Wild+Type+Glioblastoma&page=2", "query": { "condition": "IDH Wild Type Glioblastoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Wild+Type+Glioblastoma&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Wild+Type+Glioblastoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T12:59:00.305Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07185880", "title": "A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma (GBM)" ], "interventions": [ { "name": "MT-125", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myosin Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-04-01", "completion_date": "2032-02", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07185880" }, { "nct_id": "NCT07708961", "title": "Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma, IDH-Wildtype" ], "interventions": [ { "name": "Archive Sample Retrieval", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "EGFR/EGFRvIII Inhibitor WSD0922-FU", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-08-28", "completion_date": "2036-08-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07708961" }, { "nct_id": "NCT05267106", "title": "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Adult-type Diffuse Gliomas" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 83, "start_date": "2022-05-20", "completion_date": "2024-12-17", "has_results": true, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 32, "location_summary": "Beverly Hills, California • Duarte, California • Fullerton, California + 28 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05267106" }, { "nct_id": "NCT06552260", "title": "A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "Brain Tumor" ], "interventions": [ { "name": "Troriluzole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ugonma Chukwueke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-02-19", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06552260" }, { "nct_id": "NCT06641908", "title": "Anti-GD2 ADC M3554 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "M3554", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2024-11-08", "completion_date": "2027-04-16", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06641908" }, { "nct_id": "NCT04729959", "title": "Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Wildtype", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Fractionated Stereotactic Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-03-11", "completion_date": "2027-08-20", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 110, "location_summary": "Anaheim, California • Bellflower, California • Los Angeles, California + 89 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729959" }, { "nct_id": "NCT07544992", "title": "Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Astrocytoma, IDH-Mutant, Grade 4", "Recurrent Glioblastoma, IDH-Wildtype" ], "interventions": [ { "name": "Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Intracranial Catheter Placement", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-05-26", "completion_date": "2031-11-04", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07544992" }, { "nct_id": "NCT06860594", "title": "Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytoma, IDH-Mutant, Grade 2", "Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant", "Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant", "Recurrent Astrocytoma, IDH-Mutant", "Recurrent Astrocytoma, IDH-Mutant, Grade 3", "Recurrent Astrocytoma, IDH-Mutant, Grade 4", "Recurrent Glioblastoma, IDH-Wildtype" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Triapine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-07-30", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 43, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 34 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06860594" }, { "nct_id": "NCT07416188", "title": "Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Glioblastoma", "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype", "Relapsed Cancer", "Recurrent Tumor", "Glioblastoma Multiforme", "Recurring Glioblastoma", "Brain and Central Nervous System Tumors", "Glioma", "Glioblastomas", "Grade IV Astrocytoma", "GBM", "Recurrent Glioma (Glioblastoma Multiforme)", "High Grade Glioma", "Glioma, Malignant", "Brain Cancer" ], "interventions": [ { "name": "LMP744", "type": "DRUG" }, { "name": "Conventional Surgery or Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 40, "start_date": "2026-07-15", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07416188" }, { "nct_id": "NCT06283927", "title": "The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma, IDH-wildtype", "Glioblastoma Multiforme of Brain", "Glioblastoma Multiforme, Adult", "Recurrent Glioblastoma", "Astrocytoma, Malignant", "Astrocytoma of Brain" ], "interventions": [ { "name": "Re-resection", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Re-irradiation", "type": "RADIATION" }, { "name": "Experimental therapy", "type": "PROCEDURE" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Jasper Gerritsen", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 464, "start_date": "2023-01-01", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-10-17T12:59:00.305Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06283927" } ] }